Elevated pulmonary artery systolic pressure (PASP) is associated with increased mortality and morbidity in the general population and in patients with HF. [4] [5] [6] [7] [8] In the African American population, elevated PASP is independently associated with comorbidities that increase the risk of HF, such as obesity, diabetes mellitus, and hypertension.
H eart failure (HF) is associated with substantial morbidity, mortality, and cost. 1 It is common in the African American population with a prevalence of 4.5% in men and 3.8% in women. 1 Moreover, the age-adjusted incidence rate of HF is highest in African Americans compared with other ethnicities residing in Jackson, MS. 13, 14 Participants were enrolled from each of 4 recruitment pools: random, 17%; volunteer, 22%; currently enrolled in the ARIC Study, 30%; and secondary family members, 31%. The participants answered predefined questionnaires and underwent echocardiographic evaluation and spirometry at the time of first examination (2000) (2001) (2002) (2003) (2004) . The participants were followed up at regular intervals. The cohort used for the current study included participants that had echocardiography data available (n=5076), measurable tricuspid regurgitant velocity (n=3282), and follow-up contact after December 31, 2004 (n=3125).
Outcome
The main outcome is time to probable or definite HF admission after adjudication based on available data on history, physical examination, laboratory analysis, and medication use similar to those used in the ARIC Study. 15, 16 The adjudication of HF outcomes began on January 1, 2005, and HF admission data were available for a median of 3.46 years (4-1461 days) after that date. Our secondary outcome was time to death starting from the time of the index echocardiographic examination.
Exposure
The main exposure is PASP. The PASP was calculated by addition of 5 mm Hg right atrial pressure to the transtricuspid gradient measured on echocardiogram. 4 
Clinical Variables
Coronary heart disease was considered as present when the subject reported a history of myocardial infarction, abnormal stress test, prior coronary artery bypass graft surgery, or prior coronary angioplasty. Presence of diabetes mellitus was defined as a history of diabetes mellitus, use of diabetes mellitus medications, hemoglobin A1c ≥6.5, or a fasting blood glucose ≥126 mg/dL. Presence of systemic hypertension was defined as subject having a systolic blood pressure ≥140 mm Hg, or a diastolic blood pressure ≥90 mm Hg, or taking antihypertensive medications. Body mass index was categorized as normal (<25 kg/m 2 ), overweight (25 to <30 kg/m 2 ), and obese (≥30 kg/m 2 ). Severe mitral or aortic valve disease was considered as present if the qualitative assessment by echocardiography showed presence of severe mitral regurgitation, mitral stenosis, aortic regurgitation, or aortic stenosis. Heart rate was measured on a baseline ECG. History of HF was considered present if the patients responded to the questionHas a doctor ever said you had HF or congestive HF?-in affirmative at the time of first annual telephone follow-up.
Chronic lung disease was considered present if the subjects responded to the question-Has your doctor or health professional ever said you have chronic lung disease, such as bronchitis or emphysema?-in the affirmative. Cigarette smoking status was derived from interview and categorized as never smoker (one who reported having smoked <400 cigarettes in one's life), former smoker (smoked >400 cigarettes but not currently smoking), and current smoker.
Spirometry Measurements
Based on the spirometry measurements, subjects were considered to have an obstructive pattern if the forced expiratory volume in 1 sec. (FEV1)/forced vital capacity (FVC) ratio was <0.7, or a restrictive pattern if the FEV1/FVC ratio was ≥0.7 and the FVC was <80% of predicted FVC. Subjects who had neither an obstructive nor a restrictive pattern were considered as having normal spirometry.
Echocardiographic Parameters
Detailed echocardiography procedures are in the Data Supplement. 17 Briefly, echocardiograms were recorded by trained sonographers and interpreted by experienced cardiologists in the Echocardiography Reading Center at the University of Mississippi Medical Center. Standard echocardiographic views were obtained and measurements performed by the interpreting physician who was blinded to the participants' clinical data. 18 No tissue Doppler measurements were performed. The echocardiographic data used for this current study included PASP (calculated from tricuspid regurgitant jet peak gradient plus 5 mm Hg), semiquantitative ejection fraction (to nearest 5%), and left atrial diameter (measured on 2-dimensional images at endsystole). Left atrial diameter was indexed to height to adjust for body habitus. All measurements used were performed in 2-dimensional images. Valvular disease was qualitatively graded.
Statistical Analysis
We first compared the baseline clinical characteristics, pulmonary function, and echocardiographic parameters using Student test and χ 2 analysis for continuous and categorical variables, respectively.
We then used a Cox proportional hazard model to estimate the hazard ratio (HR) of HF admission using either PASP (every 10 mm Hg increment) or quartiles of PASP as main exposure. Subsequently, we adjusted our model with variables used in the ARIC HF prediction model (age, sex, coronary heart disease, diabetes mellitus, systolic blood pressure, blood pressure medication use, heart rate, smoking status, and body mass index). Race was a part of the ARIC model but was dropped as a covariate because our population is exclusively African American. Subjects who died before a HF event were censored. To confirm that censoring subjects who died (competing event) did not significantly alter the hazards of HF admission (main event), we repeated our analysis by estimating the subhazard ratios using the competing-risks regression model, according to the method of Fine and Gray. 19 Subgroup analyses were then performed to estimate the HRs using Cox proportional hazard model with either PASP as a continuous variable or elevated PASP (≥33 mm Hg, the cut-off of fourth quartile of PASP) as a categorical variable adjusted for the ARIC model in subjects with or without prior HF history, in subjects with reduced or preserved EF, and in subjects with different spirometry profiles. We also performed sensitivity analyses by excluding the subjects with (1) reduced EF, prior HF history, or severe left-sided vavular disease and (2) obstructive spirometry profile, and then estimating the HRs for HF admission for the resulting subgroup by PASP (as a continuous or categorical variable) after adjustment for the ARIC model.
We performed receiver operating characteristic (ROC) curve analyses to estimate the area under the curve using the ARIC model, ARIC model plus PASP as continuous variable, and ARIC model plus elevated PASP (≥33 mm Hg) as a categorical variable to assess if addition of PASP variables improved the discriminatory power of the ARIC model. The ROC curves were then compared for significant difference in the area under the curve.
To calculate the net reclassification improvement (NRI), the 3-year (approximate median follow-up time of the cohort) event rate was calculated for each subject using the linear prediction from the fitted model and the predicted baseline survivor function at 3 years with ARIC variables alone and with ARIC variables plus PASP, in both continuous (every 10 mm Hg increment) and dichotomous (≥33 versus <33 mm Hg) manner. Categoryless NRI was also estimated as proposed by Pencina et al. 20 Briefly, the predicted event rate of HF admission using the ARIC model alone was subtracted from the predicted event rate of HF admission using the ARIC model plus PASP continuous variable, or ARIC model plus PASP dichotomous variable for each subject and categoryless NRIs were estimated. Next, to estimate NRI based on categories of HF admission risk, we divided the event risk in categories (yearly risk: <0.5%, 0.5 to <1%, 1 to <2%, and ≥2%) and performed NRI calculations using these categories.
For our secondary outcome (time to death), we used a Cox proportional hazard model to estimate the HR of death using PASP (every 10 mm Hg increment) as main exposure and adjusted for the ARIC HF variables.
Data were 81% complete for all covariates included in the model. Missing data (9% of the study population) ranged from 0.09% (body mass index) to 18.6% (blood pressure medication use). Missing data were imputed based on 5 sets of simulated values generated from nonmissing variables using the multiple imputation method in STATA (StataCorp, College Station, TX). 21 Analyses were performed on each of the 5 data sets completed with imputed values and then combined using Rubin's combination rules to consolidate the individual estimates into a single set of estimates using the MI estimate command in STATA. 22 All analysis was performed using STATA/SE version 11.2 software (StataCorp). A 2-sided P value <0.05 was considered significant.
Results
Of the 3282 subjects who had a measurable transtricuspid gradient, we have follow-up information on HF admissions starting January 1, 2005, on 3125 subjects. Before the adjudication of HF admissions started, 48 subjects had died and 109 subjects were lost to follow-up. The median gap from index echocardiogram to initiation of HF adjudication was 898 days (275-1557 days). The median follow-up time starting January 1, 2005, was 3.46 years (4-1461 days). A total of 301 confirmed HF events occurred during the follow-up in 107 subjects (3.42% of cohort). The incidence of HF admission was 1.04% per person-year during the adjudication period. Table 1 shows the baseline clinical and echocardiographic characteristics of the cohort. The average age of the population was 56.3±12.5 years with 32.2% of subjects being men. There was a high prevalence of obesity (51.1%), hypertension (61.1%), and diabetes mellitus (24.2%). The mean PASP in the cohort was 27.9±7.3 mm Hg.
Baseline Characteristics
Subjects who were admitted with HF were older, had higher systolic blood pressure, and were more likely to have hypertension, diabetes mellitus, coronary artery disease, history of prior HF, smoking history, and an obstructive or restrictive spirometry profile. As expected, they were more likely to be on antihypertensive, antidiabetic, and statin medications. On echocardiography, subjects admitted for HF had a higher PASP (35.6±11.4 versus 27.6±6.9 mm Hg; P<0.001), reduced left ventricular ejection fraction, and higher left atrial diameter index. Fifty-six percent of subjects with HF event were in the top quartile of PASP (33-69 mm Hg) compared with 20.5% of subjects who did not have HF admissions.
The baseline characteristics of cohort categorized by the PASP quartiles are shown in Table I in the Data Supplement. Higher PASP was associated with older subjects and a higher prevalence of women, obesity, hypertension, coronary artery disease, diabetes mellitus, HF, lung disease, smoking, and obstructive and restrictive spirometry profile.
Relationship of PASP With HF Admissions
The hazard of HF admission with each 10 mm Hg increment in PASP increased by 2.75-fold (95% confidence interval [CI], 2.31-3.26). Similarly, the hazard of HF admission increased by 6.23-fold (95% CI, 3.42-11.34) in subjects with PASP between 33 and 69 mm Hg (quartile 4) compared with subjects in the first quartile with PASP between 10 and 23 mm Hg ( Table 2 ). The Figure shows the unadjusted Kaplan-Meier curves of subjects grouped by the quartiles of PASP being free of HF admission from the beginning of follow-up (time 0=December 31, 2004).
After adjustment for the ARIC HF model, the adjusted HR of HF admission with each 10 mm Hg increase in PASP was 2.03 (95% CI, 1.67-2.48) and the adjusted HR of subjects with PASP in the fourth quartile was 2.69 (95% CI, 1.43-5.06) compared with those with PASP in the first quartile ( Table 2) . The unadjusted and adjusted HRs did not significantly change on using competing risk regression model with death as a competing risk (Table II in the Data Supplement) .
The increased hazard of HF admission with elevated PASP adjusted for the ARIC HF model remained significant in the subgroups of subjects with or without prior history of HF, with preserved or reduced ejection fraction, and in subjects with normal and restrictive spirometry profiles (Table 3) . Interestingly, an elevated PASP was not associated with a significantly increased hazard of HF admission in subjects with airflow obstruction on spirometry. In the subgroup of subjects with preserved EF, no significant left-sided valvular disease, and no prior history of HF, PASP remained a significant predictor of subsequent HF admissions after adjustment for the ARIC model (adjusted HR for each 10 mm Hg increase in PASP: 1.77; 95% CI, 1.38-2.27; adjusted HR for PASP ≥33 mm Hg: 2.31; 95% CI, 1.43-3.71). Similarly, in the subgroup of subjects without obstructive spirometry profile, the adjusted hazards of HF admissions increased with higher PASP (adjusted HR for each 10 mm Hg increase in PASP: 2.13; 95% CI, 1.69-2.67; adjusted HR for PASP ≥33 mm Hg: 3.12; 95% CI, 1.99-4.91).
Addition of PASP to ARIC Prediction Model of HF Admission
The ARIC HF model performed well in predicting HF admission in our population (area under the ROC curve: 0.82; 95% CI, 0.786-0.860). Nonetheless, the addition of PASP variable to the model resulted in a significant improvement in the area under the ROC curve both as a continuous variable (area under the ROC curve: 0.85; 95% CI, 0.81-0.88; P=0.02) and as a dichotomous variable (area under the ROC curve: 0.84; 95% CI, 0.81-0.88; P=0.03).
In net reclassification analysis using 4 risk categories (yearly risk of HF event: <0.5%, 0.5 to <1%, 1 to <2%, and ≥2%), the addition of PASP (≥33 mm Hg) to the ARIC model resulted in a NRI of 15.1% (Table 4) . Using the same risk categories, the NRI was 11.3% (Table III in 
Relationship of PASP With Overall Survival
As opposed to HF admission events, survival data were available starting from the date of the index echocardiogram. During a median follow-up of 2102 days (n=3240; range 20-3002 days), 201 subjects died. The unadjusted hazard of death with every 10 mm Hg increase in PASP was 1.87-fold (95% CI, 1.62-2.17; P<0.001). After adjusting for ARIC variables, the HR for death with every 10 mm Hg increase in PASP remained significantly increased at 1.38 (95% CI, 1.18-1.62; P<0.001).
Discussion
In this study, we show that in an ambulatory, community-based African American cohort with a yearly HF admission risk of ≈ 1%, having an elevated PASP is associated with increased risk of future HF admission and provides incremental value in predicting hospitalization risk compared with a validated HF model. After adjusting for comorbidities, participants with a PASP ≥33 mm Hg had a 2.7-fold increase in the hazard for a HF admission compared with those with PASP <24 mm Hg, and for every 10 mm Hg increase in PASP, there was a doubling of the hazard for HF admission.
HF is an emerging crisis in the United States with >1 million hospitalizations annually that are associated with substantial morbidity, mortality, and costs. 23 Notably, patients hospitalized for HF are at high risk for all-cause rehospitalization, with a 1-month readmission rate of 25%. 24 Although screening asymptomatic patients is not recommended, Doppler echocardiography is frequently used in the assessment of patients with cardiovascular comorbidities. PASPs are easily obtained in about two thirds of patients undergoing echocardiograms. 4, 9 Our data suggest that PASP can be used to identify patients who are at risk for subsequent HF admission, especially in patients with preserved EF. Because at this time we do not know if elevated PASP is a modifiable risk factor or a target for treatment in HF, the management of these at-risk patients would include aggressive control of their modifiable risk factors, such as hypertension, diabetes mellitus, metabolic syndrome and obesity, and guideline-recommended therapy. 25 As novel therapies become available especially for HF with preserved ejection fraction, it may be reasonable to study their benefit in these at-risk subjects to prevent HF admissions. The relationship between PASP and HF events was independent of clinical comorbidities and was significant in subgroups with either reduced or preserved ejection fraction. Both left ventricular systolic and diastolic dysfunction are associated with elevations in left atrial pressure that result in higher PASP by passive mechanism or by increase in vascular remodeling (reactive). However, it is surprising how relatively modest elevations in PASP, to levels not typically considered clinically significant, were related to subsequent HF hospitalizations in our analysis. Similar findings were noted in other studies, where mild to modest elevation on PASP related to mortality 4 and to HF events in patients with stable coronary artery disease 7 or acute myocardial infarction. 8 We speculate that the underlying mechanism may be related to progression of increased vascular stiffness or preclinical left atrial hypertension that ultimately manifests as clinical HF. Because elevated PASP independently predicted HF admissions in participants with or without a prior self-reported history of HF, our data suggest that elevated PASP can be used as an additional marker to identify patients in preclinical stages (stage A or stage B) of HF. 25 It has been shown that HF is common in patients with chronic obstructive pulmonary disease and is frequently unrecognized. 26, 27 However, in subgroup analysis, we found that PASP did not predict HF hospitalization in participants with airflow obstruction on spirometry. Given that the obstructive spirometry phenotype may be independently related to elevated PASP in African Americans because of reasons other than cardiac function (eg, chronic pulmonary disease and hypoxia-associated vascular remodeling), 9 it is not surprising that an association between elevated PA pressures and HF hospitalization in this subgroup of subjects was not observed. Hence, alternative risk predictors, such as brain natriuretic peptide, may be more relevant in these patients.
We report that addition of PASP, either as a continuous or dichotomous variable, significantly improved the area under the ROC curve of an existing HF prediction model. We used the ARIC model as our baseline model to predict HF events because other models such as ABC (Aging and Body Composition) and Framingham HF prediction models 11, 12 did not include a significant proportion of African Americans in their respective cohorts. Moreover, the ARIC model has been shown to perform better in a cohort with African Americans compared with others. 10 Indeed, 30% of JHS participants were also part of the ARIC cohort that was used to develop the ARIC model. The baseline ARIC model performed extremely well in our study cohort considering the reported area under the ROC curve used to design the model in the ARIC cohort (c index of 0.77-0.79). 10 Despite the already good performance of the ARIC model, addition CI indicates confidence interval; HF, heart failure; HR, hazard ratio; LV, left ventricular; and PASP, pulmonary artery systolic pressure.
*Age, sex, coronary heart disease, diabetes mellitus, systolic blood pressure, blood pressure medication use, heart rate, smoking status, and body mass index.
of the PASP significantly improved the discriminatory power in predicting HF events. The NRI analysis confirmed that the addition of PASP for identifying high-risk subjects reclassifies 11% to 15% of the subjects into more appropriate yearly risk categories. The NRI for PASP is of similar magnitude to the NRI for addition of commonly used biomarkers such as N-terminal prohormone of brain natriuretic peptide (NRI: 13.5% when added to the ARIC model) 10 or C-reactive protein (NRI: 11.8% when added to a multivariable prediction model in the Framingham Offspring cohort in predicting coronary heart disease events). 28 Future studies will be needed to determine if PASP and N-terminal prohormone of brain natriuretic peptide have overlapping or synergistic effects when added together to the ARIC model.
Our study has some limitations. The adjudication of HF events started in 2005. Hence we do not have any event data between the baseline study enrollment dates (2000) (2001) (2002) (2003) (2004) and 2005. Thus, we may be underestimating the association between PASP and HF hospitalization assuming that the HF event rates remained constant throughout the study period. PASPs can be dynamic. The echocardiography was performed at the baseline visit, and there were no repeated measures available for PASP in this cohort. We are, therefore, unable to ascertain if temporal trends in PASP may relate to HF events or mortality. Despite this limitation, our results suggest that even modestly elevated PASP can serve as a significant risk factor for remote HF events and that the underlying pathophysiology may predate the actual event by years similar to other chronic diseases such as diabetes mellitus and hypertension. There were no inferior vena cava measurements, so we used an assumed right atrial pressure (RAP) of 5 mm Hg as done by others in a population-based cohort, 4 which may have led to underestimation of PA pressure in subjects with more elevated RAPs. Also, a right heart catheterization-derived PASP is more accurate, which unfortunately is not feasible or practical to perform in population studies. Despite its limitations and inability to accurately assess PA pressures, Doppler echocardiography is frequently used to estimate the PASP. 4 Hence, it is possible that the lack of precision in measured PASP may have affected the association between estimated PASP and HF admission. History of HF is self-reported and as such subject to recall bias. Thus, we are unable to accurately discern between the incident and recurrent HF hospitalizations in the current study.
In conclusion, we report that elevated PASP predicts HF admissions and mortality in African Americans independent of clinical comorbidities and provides incremental value as a risk assessment marker for future HF hospitalizations. Identification of these at-risk subjects using PASP measurements may be helpful in targeting aggressive risk factor modification. Future studies are needed to confirm the validity of our findings in other populations.
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